✅ Milestone: We’ve completed enrollment of the first cohort in our Phase 1b trial of PTM-101 for #pancreaticcancer ahead of expectations! 🚀 Another step forward in advancing localized therapies for #cancer patients.
📣 Full release: https://t.co/5z15GDIX39
Next week at #FBW2025, CEO Laura Indolfi joins the Biotech CEO Insights panel 🎤 in Boston. We're proud to be part of the biotech conversation shaping the future of science 🔬 and patient care 💜.
📅 Oct 7–9 | Encore Boston Harbor
#FBW2025#biotech
https://t.co/6BMFnnXdOl
🔬 #ICYMI: Our Phase 1b trial in #pancreaticcancer is rapidly enrolling across the U.S., evaluating a promising new approach to #chemotherapy: an absorbable, long-lasting, high-dose drug patch.
🔗 Learn more: https://t.co/5z15GDIX39
#ICYMI: We treated the first participant in our Phase 1b clinical trial of PTM-101 for pancreatic #cancer. 🚀 The right anti-cancer drugs exist—but getting it there is the challenge. 💊 Learn how PTM-101 delivers chemotherapy directly to the tumor: https://t.co/DQxbCH1zXg
🎉 Big news! We’ve treated our first participant with PTM-101, an absorbable, long-lasting high-dose chemotherapy patch, in our clinical trial for #PDAC. It’s a huge step toward powerful, localized cancer care for solid #tumors. 🧬
🔗 Full release: https://t.co/DQxbCH1zXg
Thrilled our CEO @LauraIndolfi will be among featured panelists discussing "Women-led Innovation: Overcoming Challenges as a Female Entrepreneur & Executive in Medtech", taking place at #LSIEurope23 in September. If you’re attending, make sure to connect! #medtech@lsintelligence
A new day, a new panel announced on the #RoadToEurope 🌅
📣 We’re excited to introduce the panel, “Women-led Innovation: Overcoming Challenges as a Female Entrepreneur & Executive in Medtech,” taking place at #LSIEurope23 in Barcelona, Spain.
Thanks @BosBizJournal & @MALifeSciences for featuring our CEO @LauraIndolfi as part of the “Women who lead in Life Sciences” Serie!We are working relentlessly to change the status quo in cancer treatment by bringing the fight directly at the tumor🎯! #AttackingCancerAtTheSource™️
Thrilled to welcome Leslie Sloan as PanTher's SVP of Development & Operations! With a stellar track record in driving execution and delivering successful drug development programs, she adds immense value to our team.
#TherapeuticsOnTarget#AttackingCancerAtTheSource#leadership
Excited to be here at #AHPBA23 to see the amazing progress in the field & interact with the community. Looking forward to connecting with surgeons/KOLs regarding our upcoming clinical trial. Reach out to learn more!
@AHPBA#TherapeuticsOnTarget🎯 #AttackingCancerAtTheSource™️
Happy 6!!!! Such a special number for us!! Today our team (of 6) had a lunch party to celebrate🎂
- 6 Years with our first employee
- 6 Months with our Director of Ops
- 60 Days with our new Scientist
looking forward to increasing the numbers to celebrate
#DreamTeam#hiringsoon
2022 has been a fruitful year, full of goals achieved💥 & progress made 🚀to serve as foundation for more milestones to come. We can't wait to share the fruit of our hard work in Attacking Cancer at the Source™ by bringing #TherapeuticsOnTarget🎯 Looking forward to 2023 🎉🎇